Immune response to octavalent diphtheria- and tetanus-conjugated pneumococcal vaccines is serotype- and carrier-specific: the choice for a mixed carrier vaccine.

2.50
Hdl Handle:
http://hdl.handle.net/2336/30752
Title:
Immune response to octavalent diphtheria- and tetanus-conjugated pneumococcal vaccines is serotype- and carrier-specific: the choice for a mixed carrier vaccine.
Authors:
Sigurdardottir, Sigurveig T; Ingolfsdottir, Gunnhildur; Davidsdottir, Katrin; Gudnason, Thorolfur; Kjartansson, Sveinn; Kristinsson, Karl G; Bailleux, Fabrice; Leroy, Odile; Jonsdottir, Ingileif
Citation:
Pediatr. Infect. Dis. J. 2002, 21(6):548-54
Issue Date:
1-Jun-2002
Abstract:
BACKGROUND: Development of protein-conjugated pneumococcal vaccines for infants has led to formulations that are immunogenic in the age group at highest risk for pneumococcal diseases. This study focuses on the search for an optimal formulation. METHODS: In a randomized trial Icelandic infants (n = 160) were immunized at age 3, 4 and 6 months with one of two octavalent pneumococcal conjugate vaccines (serotypes 3, 4, 6B, 9V, 14, 18C, 19F and 23F conjugated to diphtheria toxoid (PncD) or tetanus protein (PncT) followed with a booster of either the same conjugate or 23-valent polysaccharide vaccine at 13 months. Safety data were collected after each vaccination, and IgG responses (enzyme-linked immunosorbent assay) were measured at 3, 4, 6, 7, 13 and 14 months. RESULTS: Both conjugates were safe and caused fewer local reactions than the routine vaccines (P < 0.0001). At 7 months both groups had significant IgG response to all serotypes. The geometric mean concentration range was 0.35 to 4.09 and 0.65 to 3.38 microg/ml for PncD and PncT, respectively, with 88.2 to 100% and 92.4 to 100% of subjects reaching > or = 0.15 microg/ml. The PncD gave better primary responses to serotypes 3, 9V and 18C, whereas PncT gave better response to serotype 4. Similar responses were induced to the other serotypes. Good booster IgG responses were obtained in all vaccine groups; 97.5 to 100% of subjects reached > or = 1 microg/ml. CCONCLUSIONS: Both octavalent pneumococcal conjugates were safe and immunogenic in infants. Based on the results from this and similar trials, a mixed diphtheria and tetanus pneumococcal conjugate vaccine was designed to provide the optimal immune response to each serotype.
Description:
To access publisher full text version of this article. Please click on the hyperlink in Additional Links field
Additional Links:
http://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=N&PAGE=fulltext&AN=00007632-200208010-00010&LSLINK=80&D=ovft

Full metadata record

DC FieldValue Language
dc.contributor.authorSigurdardottir, Sigurveig T-
dc.contributor.authorIngolfsdottir, Gunnhildur-
dc.contributor.authorDavidsdottir, Katrin-
dc.contributor.authorGudnason, Thorolfur-
dc.contributor.authorKjartansson, Sveinn-
dc.contributor.authorKristinsson, Karl G-
dc.contributor.authorBailleux, Fabrice-
dc.contributor.authorLeroy, Odile-
dc.contributor.authorJonsdottir, Ingileif-
dc.date.accessioned2008-07-01T11:04:50Z-
dc.date.available2008-07-01T11:04:50Z-
dc.date.issued2002-06-01-
dc.date.submitted2008-07-01-
dc.identifier.citationPediatr. Infect. Dis. J. 2002, 21(6):548-54en
dc.identifier.issn0891-3668-
dc.identifier.pmid12182380-
dc.identifier.urihttp://hdl.handle.net/2336/30752-
dc.descriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Links fielden
dc.description.abstractBACKGROUND: Development of protein-conjugated pneumococcal vaccines for infants has led to formulations that are immunogenic in the age group at highest risk for pneumococcal diseases. This study focuses on the search for an optimal formulation. METHODS: In a randomized trial Icelandic infants (n = 160) were immunized at age 3, 4 and 6 months with one of two octavalent pneumococcal conjugate vaccines (serotypes 3, 4, 6B, 9V, 14, 18C, 19F and 23F conjugated to diphtheria toxoid (PncD) or tetanus protein (PncT) followed with a booster of either the same conjugate or 23-valent polysaccharide vaccine at 13 months. Safety data were collected after each vaccination, and IgG responses (enzyme-linked immunosorbent assay) were measured at 3, 4, 6, 7, 13 and 14 months. RESULTS: Both conjugates were safe and caused fewer local reactions than the routine vaccines (P < 0.0001). At 7 months both groups had significant IgG response to all serotypes. The geometric mean concentration range was 0.35 to 4.09 and 0.65 to 3.38 microg/ml for PncD and PncT, respectively, with 88.2 to 100% and 92.4 to 100% of subjects reaching > or = 0.15 microg/ml. The PncD gave better primary responses to serotypes 3, 9V and 18C, whereas PncT gave better response to serotype 4. Similar responses were induced to the other serotypes. Good booster IgG responses were obtained in all vaccine groups; 97.5 to 100% of subjects reached > or = 1 microg/ml. CCONCLUSIONS: Both octavalent pneumococcal conjugates were safe and immunogenic in infants. Based on the results from this and similar trials, a mixed diphtheria and tetanus pneumococcal conjugate vaccine was designed to provide the optimal immune response to each serotype.en
dc.language.isoenen
dc.publisherWilliams & Wilkinsen
dc.relation.urlhttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=N&PAGE=fulltext&AN=00007632-200208010-00010&LSLINK=80&D=ovften
dc.subject.meshAntibodies, Bacterialen
dc.subject.meshAntibody Specificityen
dc.subject.meshDiphtheria-Tetanus Vaccineen
dc.subject.meshHumansen
dc.subject.meshIcelanden
dc.subject.meshImmunization Scheduleen
dc.subject.meshInfanten
dc.subject.meshPneumococcal Vaccinesen
dc.subject.meshSensitivity and Specificityen
dc.subject.meshVaccines, Conjugateen
dc.titleImmune response to octavalent diphtheria- and tetanus-conjugated pneumococcal vaccines is serotype- and carrier-specific: the choice for a mixed carrier vaccine.en
dc.typeArticleen
dc.contributor.departmentDepartment of Immunology, Landspitali-University Hospital, Reykjavik Iceland. veiga@landspitali.isen
dc.identifier.journalPediatric infectious disease journalen

Related articles on PubMed

All Items in Hirsla are protected by copyright, with all rights reserved, unless otherwise indicated.